• Founded by Richard Driansky, Esq. and John S. Lollar M.D.
• Secures exclusive option from Emory University to recombinant porcine factor VIII (rpfVIII) and low immunogenic factor VIII

1998

• Secures exclusive, worldwide license from Emory to rpfVIII and low immunogenic factor VIII
• Enters into strategic alliance with French drug maker Ipsen (formerly Beaufour Ipsen) to develop and commercialize the factor VIII molecules licensed from Emory.
• Ipsen invests in Octagen

1999

• Receives first milestone payment from Ipsen for rpfVIII development
• Receives NIH STTR Phase I grant for low immunogenic factor VIII

2000

• Completes second round financing with Philadelphia area venture fund Bal Cap Biotech and Ipsen
• Secures from the University of Minnesota exclusive, worldwide rights to BOEC gene therapy technology
• Receives NIH SBIR Phase I grant for rpfVIII
• Receives second milestone payment from Ipsen for rpfVIII development

2001

• Receives two year NIH SBIR Phase 2 grant for rpfVIII
• Commences pre-clinical development program for rpfVIII
• BOECs transfected with human factor VIII achieve and maintain high levels of human factor VIII expression in immune deficient mice, corresponding to normal or even supra-normal human levels (BLOOD, vol. 99, no.2, January 15, 2002, pages 457 – 462)
• Receives third milestone payment from Ipsen for rpfVIII development
• Receives first milestone payment from Ipsen for recombinant low immunogenic factor VIII development

2002

• Files Investigational New Drug Application for rpfVIII
• Receives NIH STTR Phase 1 grant for BOECs
• Receives fourth milestone payment from Ipsen for rpfVIII development

2003

• Commences Phase I clinical trial of rpfVIII in U.S. and U.K

2005

• Commences Phase II clinical trial of rpfVIII in U.S. and abroad